Truqap Plus Faslodex Recommended for Approval in the EU by CHMP for Advanced ER-Positive Breast Cancer
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or …